Next Generation Anti-Infectives that Mimic Natural Human Antimicrobial Peptides
Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides.
Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
Maxwell Biosciences is a preclinical stage drug platform company partnering with large pharma companies to develop an entirely new class of patented low molecular weight drug candidates that destroy SARS-CoV-2, the COVID virus, as well as other viruses and infectious pathogens (including fungal and bacterial pathogens). Maxwell's first-in-class CLAROMER™ brand drug discovery platform mimics natural human immune system antimicrobial and antiviral peptides.
Maxwell Biosciences has benefitted from over $35M of non-dilutive grants and awards from governments around the world to validate their science and technology, including studies by US Govt-funded labs confirming that Maxwell's lead drug candidate has direct virucidal action against Herpes virus (HSV-1) and SARS-CoV-2, the COVID virus. Additionally, live mouse safety data at Texas A&M show Maxwell's drugs benefit from a tissue-safe toxicology profiles, and live mouse studies from the Baylor College of Medicine show breakthrough fungicidal action with CLAROMER™ brand compounds against lethal fungal infections of the upper-respiratory tract. These findings support the expected safety and effectiveness of Maxwell's “multi-asset, multi-target” anti-infectives drug platform. Maxwell's drug platform is supported by a granted patent portfolio and is strongly positioned in the fight against emergent viral pandemics and a broad spectrum of evolving infectious pathogens. Maxwell is raising funds for advanced preclinical and human trials.
Location: United States
Employees: 11-50
Total raised: $30.8M
Founded date: 2016
Investors 6
| Date | Name | Website |
| - | Angel Star... | angelstarv... |
| - | LoftyInc C... | loftyinc.v... |
| - | Longevityt... | longevityt... |
| 13.04.2023 | Keiretsu F... | keiretsufo... |
| - | LoftyInc C... | loftyincca... |
| - | Endless Fr... | endlessfro... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 07.08.2025 | - | $20M | - |
| 10.03.2022 | Seed | $10.8M | - |
Mentions in press and media 8
| Date | Title | Description |
| 18.12.2025 | Havih, a Maxwell Biosciences Subsidiary, Announces Partnership with the Government of Andhra Pradesh | Pulivendula, Andhra Pradesh, India Havih Envirosciences, an Indian citizen-owned and operated life sciences company and subsidiary of Maxwell Biosciences, announced a strategic partnership with the Government of Andhra Pradesh to establish ... |
| 07.08.2025 | Maxwell Biosciences Closes $20M Financing Round | Maxwell Biosciences, an Austin, TX-based health technology company providing a new category of immune-inspired small molecules called Claromers, raised $20M in funding. Backers were not disclosed. The company intends to use the funds to exp... |
| 11.06.2025 | Maxwell Biosciences (Life Sciences, '22-23) exclusive ClaromerTM antiseptic technology, which protects skin while maintaining the natural microbiota, is a daring entry into the $500 billion cosmetics ... | - |
| 11.03.2025 | Maxwell Biosciences (Life Sciences, '22-23) has signed a Cooperative Research and Development Agreement (CRADA) with the U.S. Naval Medical Research Command to create treatments for dengue virus infec... | - |
| 10.03.2022 | Maxwell Biosciences Grabs $10.8M Seed Round | AUSTIN, TX, Maxwell Biosciences today announced that it has closed an oversubscribed $10.8 million Seed Capital raise. >> Click here for more funding data on Maxwell Biosciences >> To export Maxwell Biosciences funding data ... |
| 10.03.2022 | Maxwell Biosciences Raises $10.8M in Seed Funding Round | Maxwell Biosciences, an Austin, TX-based preclinical stage drug platform company, raised $10.8M in Seed funding. The round was led by DecentraNet with participation from Star Lake Bioventures, Joseph Ventures, Keiretsu Forum and members of ... |
| 09.04.2021 | David Evans Shaw Backs Maxwell Biosciences | David Evans Shaw Maxwell Biosciences, an Austin, Texas-based developer of next generation virucides, secured a major investment from pharmaceutical investor-entrepreneur David Evans Shaw, Managing Partner of Black Point Group. The amount of... |
| - | Maxwell Biosciences | “Leading research scientists developing pathogen agnostic anti-infective biodefense technology able to tackle bacteria, fungi and viruses, designed to extend healthspan.” |